Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Myocardial Ischemia » Coronary Disease
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Myocardial Ischemia » Coronary Disease
Description
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. MeSH
Hierarchy View
Subtype Terms (7)
Coronary Aneurysm
5 approved drugs
Coronary Artery Disease
410 drugs (236 approved, 174 experimental)
Coronary Occlusion
8 drugs (7 approved, 1 experimental)
Coronary Stenosis
23 drugs (15 approved, 8 experimental)
Coronary-Subclavian Steal Syndrome
Coronary Thrombosis
3 drugs (2 approved, 1 experimental)
Coronary Vasospasm
16 drugs (14 approved, 2 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (86)
Phase 3 Indicated Drugs (64)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (32)
Organization Involved with Phase 4 Indications (223)
Ada and Hagbart Waages Humanitarian and Charity Foundation
Alf and Aagot Helgesens Research Foundation
Aristotle University of Thessaloniki
Associations for Establishment of Evidence in Interventions
Atlanta Heart Specialists, LLC
Boryung Pharmaceutical Company
Cardiovascular Institute of the South Clinical Research Corporation
CardioVascular Research Foundation, Korea
Catholic University of Sacred Heart, Rome
Centro de estudios en Cardiologia Intervencionista
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Clinical Hospital Center Zemun
Daewoong Pharmaceutical Co. LTD.
Fundação de Amparo à Pesquisa do Estado de São Paulo
Guangdong Provincial Hospital of Traditional Chinese Medicine
Haugaard, Steen Bendix, M.D., DMSc
Heart and Stroke Foundation of Canada
Hellenic Institute for the Study of Sepsis
Icahn School of Medicine at Mount Sinai
IHF GmbH - Institut für Herzinfarktforschung
Imam Abdulrahman Bin Faisal University
Institute for Clinical Effectiveness, Japan
Japan Cardiovascular Research Foundation
Jiangsu Kangyuan Pharmaceutical Co. Ltd
King Fahad Armed Forces Hospital
Lepu Medical Technology (Beijing) Co., Ltd.
Les Laboratoires des Médicaments Stériles
Methodist Cancer Center, Houston, Texas
National Cheng Kung University
National Health and Medical Research Council, Australia
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
National Natural Science Foundation of China
Pauls Stradins Clinical University Hospital
People's Liberation Army of China
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Samjin Pharmaceutical Co., Ltd.
Shanghai Hutchison Pharmaceuticals Limited
Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai Xuhui District Central Hospital
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Taipei Veteran General hospital
The Baruch Padeh Medical Center, Poriya
The Norwegian Council on Cardiovascular Disease
The University of Texas, Dallas
Ukrainian Medical Stomatological Academy
University Hospital of Limerick
University of California, Los Angeles
University of California, San Francisco
University of Campania Luigi Vanvitelli
University of Roma La Sapienza
University of Texas, San Antonio
Vita-Salute University of Milano. Italy
Organization Involved with Phase 3 Indications (159)
Advanced Accelerator Applications
Associazione Nazionale Medici Cardiologi Ospedalieri
Boston Health and Hospitals Department
Catharina Ziekenhuis Eindhoven
Centers for Disease Control and Prevention (CDC)
Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway
Greater Baltimore Medical Center
Institute of Cardiology, Warsaw, Poland
Institut National de la Santé Et de la Recherche Médicale, France
Juvenile Diabetes Research Foundation
Maryland Medical Research Institute
National Cancer Institute (NCI)
National Heart Institute, Bach Mai Hospital, Vietnam
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
New England Research Institutes
Novosibirsk Research Institute of Circulation Pathology
Oklahoma Medical Research Foundation
Pacific Health Research Institute
Palo Alto Medical Research Foundation
Pontifícia Universidade Católica do Paraná
Salt Lake Clinic Research Foundation
Steno Diabetes Center Copenhagen
St. Joseph Hospital Health Center
Taichung Veterans General Hospital
Translational Research Informatics Center, Kobe, Hyogo, Japan
University of California, Berkeley
University of California, Davis
University of California, San Diego
University of Colorado, Denver
University of North Carolina at Chapel Hill
University of Southern California
University of Western Brittany
Venezuelan Foundation of Heart Failure
Virginia Commonwealth University
Washington University in St. Louis
Zhejiang Hisun Pharmaceutical Co. Ltd.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (77)
Cardiovascular Imaging Technologies
Centre for Digestive Diseases, Australia
Changchun University of Chinese Medicine
Fundacion Investigacion y Desarrollo
German Center for Cardiovascular Research e. V. (DZHK)
Hellenic Cardiovascular Research Society
Jacksonville Center for Clinical Research
National Institute of Mental Health (NIMH)
Norwegian University of Science and Technology
Papworth Hospital NHS Foundation Trust
Platelet and Thrombosis Research L.L.C
Polpharma Foundation for Development of Polish Pharmacy and Medicine
Richardson Centre for Functional Foods and Nutraceuticals
South-Eastern Norway Regional Health Authority
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (67)
Beijing Municipal Health Bureau
Canadian Collaborative Research Network
Chinese People's Armed Police Forces
Conselho Nacional de Desenvolvimento Científico e Tecnológico
D'Annunzio University of Chieti–Pescara
Federal University of Rio de Janeiro
Guangzhou University of Chinese Medicine
Hamilton Health Sciences Corporation
Henan Institute of Cardiovascular Epidemiology
Medical Research Foundation, Oregon
New York City Health and Hospitals Corporation
Oregon Health and Science University
Rio de Janeiro State University
Saint Francis Memorial Hospital
Shaanxi Provincial People's Hospital
State Health Center, Budapest, Hungary
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
